New drug combo tested to help hearts last longer after transplant

This study is testing whether adding a drug called Thymoglobulin to the standard anti-rejection medications helps prevent a serious complication called cardiac allograft vasculopathy (CAV), which is a form of artery disease in the transplanted heart. The trial will involve about 60 adults receiving their first heart transplant, with half receiving the extra drug for five days right after surgery. Researchers will monitor participants for one year to see if the added treatment reduces rejection and other problems.